Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Mallinckrodt
Medtronic
Harvard Business School
Colorcon

Last Updated: April 1, 2023

OXYCONTIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $100
Remove trial restrictions


Which patents cover Oxycontin, and when can generic versions of Oxycontin launch?

Oxycontin is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are twenty-one patents protecting this drug and five Paragraph IV challenges.

This drug has five hundred and sixty-two patent family members in forty-nine countries.

The generic ingredient in OXYCONTIN is oxycodone hydrochloride. There are nineteen drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the oxycodone hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Oxycontin

A generic version of OXYCONTIN was approved as oxycodone hydrochloride by SPECGX LLC on June 30th, 2004.

  Sign Up

Drug patent expirations by year for OXYCONTIN
Drug Prices for OXYCONTIN

See drug prices for OXYCONTIN

Drug Sales Revenue Trends for OXYCONTIN

See drug sales revenues for OXYCONTIN

Recent Clinical Trials for OXYCONTIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
3D MedicinesPhase 2
Medical College of WisconsinPhase 2
Khashayar VaziriPhase 2

See all OXYCONTIN clinical trials

Pharmacology for OXYCONTIN
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Anatomical Therapeutic Chemical (ATC) Classes for OXYCONTIN
Paragraph IV (Patent) Challenges for OXYCONTIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
OXYCONTIN Extended-release Tablets oxycodone hydrochloride 20 mg 022272 2 2010-10-29
OXYCONTIN Extended-release Tablets oxycodone hydrochloride 15 mg 022272 1 2010-10-28
OXYCONTIN Extended-release Tablets oxycodone hydrochloride 10 mg 022272 1 2010-10-25
OXYCONTIN Extended-release Tablets oxycodone hydrochloride 30 mg, 60 mg and 80 mg 022272 1 2010-10-18
OXYCONTIN Extended-release Tablets oxycodone hydrochloride 40 mg 022272 1 2010-10-04

US Patents and Regulatory Information for OXYCONTIN

OXYCONTIN is protected by twenty-one US patents.

Patents protecting OXYCONTIN

Abuse-proofed dosage form
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE

Abuse-proofed dosage form
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Process for preparing oxycodone compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Crush resistant delayed-release dosage forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Tamper resistant dosage forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Tamper resistant dosage forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE

Abuse-proofed dosage form
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE

Tamper resistant dosage forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE

Tamper resistant dosage forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Tamper resistant dosage forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Tamper resistant dosage forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Tamper resistant dosage forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE

Tamper resistant dosage forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Tamper resistant dosage forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE

Oxycodone compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Abuse-proofed dosage form
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Tamper resistant dosage forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Tamper resistant dosage forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Tamper resistant dosage forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-004 Apr 5, 2010 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-005 Apr 5, 2010 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-002 Apr 5, 2010 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-002 Apr 5, 2010 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OXYCONTIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-005 Apr 5, 2010 ⤷  Sign Up ⤷  Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-002 Apr 5, 2010 ⤷  Sign Up ⤷  Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-005 Apr 5, 2010 ⤷  Sign Up ⤷  Sign Up
Purdue Pharma Lp OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272-006 Apr 5, 2010 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for OXYCONTIN

See the table below for patents covering OXYCONTIN around the world.

Country Patent Number Title Estimated Expiration
Portugal 2311459 ⤷  Sign Up
Croatia P20110147 ⤷  Sign Up
Serbia 51591 FARMACEUTSKI DOZNI OBLICI REZISTENTNI NA ZLOUPOTREBU KOJI SADR┼ŻE OPIOIDNI ANALGETIK (TAMPER RESISTANT ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING AN OPIOID ANALGESIC) ⤷  Sign Up
Finland 113152 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for OXYCONTIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1685839 92292 Luxembourg ⤷  Sign Up PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Dow
Medtronic
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.